AEON Biopharma (AEON) Research & Development (2022 - 2026)
AEON Biopharma (AEON) posted Research & Development of $1.6 million for Q4 2025, up 169.51% sequentially from $597000.0 in Q3 2025, and down 47.02% YoY from $3.0 million in Q4 2024.
AEON Biopharma (AEON) Research & Development (2022 - 2026) Analysis & Trends
AEON Biopharma has reported Research & Development for 4 years, with the latest figure at $1.6 million in Q4 2025.
- Quarterly Research & Development fell 47.02% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 71.12% YoY) and the FY2025 annual result came in at $4.1 million, down 71.13% from the prior year.
- Research & Development improved to $1.6 million in Q4 2025 per AEON's latest filing, from $597000.0 in the prior quarter.
- Over five years, Research & Development peaked at $9.5 million in Q4 2022 and troughed at $597000.0 in Q3 2025.
- A 4-year average of $4.6 million and a median of $4.4 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development declined 14.56% in 2023, then tumbled 85.61% in 2025.
- Over 4 years, Research & Development stood at $9.5 million in 2022, then sank by 32.96% to $6.4 million in 2023, then plunged by 52.46% to $3.0 million in 2024, then sank by 47.02% to $1.6 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $1.6 million, $597000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | AEON Biopharma | 10.06 Mn | 6.62 Mn | - | 2.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.94 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 597,000.00 |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 825,000.00 |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 972,000.00 |
| Jun 30, 2024 | 4.44 Mn |
| Mar 31, 2024 | 5.73 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | 9.03 Mn |
| Mar 31, 2023 | 9.21 Mn |
| Dec 31, 2022 | 9.53 Mn |
| Sep 30, 2022 | 7.48 Mn |